Charles River Laboratorie (CRL) Misses Q2 EPS by 1c; Extends Agreement with AstraZeneca (AZN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
| ASTRAZENECA PLC (NASDAQ: AZN) | Delayed: 92.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.77 | 52 Week High | $35.04 | |||
| Open | $92.77 | 52 Week Low | $26.97 | |||
| Day High | $92.77 | P/E | N/A | |||
| Day Low | $92.77 | EPS | $0.00 | |||
| Volume | 5,465,665 | |||||
| CHARLES RIVER LABORATORIE (NYSE: CRL) | Delayed: 359.41 -16.69 (4.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $376.10 | 52 Week High | $89.18 | |||
| Open | $372.99 | 52 Week Low | $65.70 | |||
| Day High | $374.56 | P/E | 167.17 | |||
| Day Low | $351.98 | EPS | $2.15 | |||
| Volume | 1,503,508 | |||||
